Simulations Plus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024
July 02, 2024 at 04:08 pm
Share
Simulations Plus, Inc. reported earnings results for the third quarter and nine months ended May 31, 2024. For the third quarter, the company reported revenue was USD 18.54 million compared to USD 16.23 million a year ago. Net income was USD 3.14 million compared to USD 4.01 million a year ago. Basic earnings per share from continuing operations was USD 0.16 compared to USD 0.2 a year ago. Diluted earnings per share from continuing operations was USD 0.15 compared to USD 0.2 a year ago.
For the nine months, revenue was USD 51.35 million compared to USD 43.95 million a year ago. Net income was USD 9.11 million compared to USD 9.43 million a year ago. Basic earnings per share from continuing operations was USD 0.46 compared to USD 0.47 a year ago. Diluted earnings per share from continuing operations was USD 0.45 compared to USD 0.46 a year ago.
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. Its segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. The Company also provides tech-enabled training and compliance solutions for clinical trial investigators and site staff.